Shots: The US FDA has approved NeuroSphere Virtual Clinic that allows a patient to communicate with a physician and remotely receive stimulation settings in real-time regardless of location NeuroSphere Virtual […]readmore
Tags : Launches
Biosimilars
Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory
Shots: Health Canada has authorized Idacio on Oct 30, 2020, for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology, […]readmore
Shots: Health Canada has approved Hulio, a biosimilar referencing AbbVie’s Humira (adalimumab), which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab […]readmore
Shots: The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround […]readmore
Shots: The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field […]readmore
Shots: UCB invested $29.3M in Nile and as majority shareholder, will be the Board of Directors of Nile with future opportunities to acquire insights and data from Nile’s platform Nile […]readmore
Shots: The launch of Tacrolimus capsules follows the approval of the US FDA in Nov’20 and emphasizes Biocon activity to make affordable healthcare accessible Tacrolimus is particularly effective in treating […]readmore
Shots: NOWDiagnostics has received a CE mark approval for its ADEXUSDx COVID-19 Ab fingerstick test across 28 countries in the EU. The test first received CE mark for use in […]readmore
Shots: Google has launched the Google Health Studies app for Android phones with the initial focus on respiratory diseases such as COVID-19. The app is now available in the play […]readmore
Shots: Qiagen launches QuantiFERON SARS-CoV-2 RUO solution that detects T-cell responses of the human immune system to the pathogen for COVID-19 Studies suggested that T-cell response to SARS-CoV-2 declines more […]readmore